Finn
URGN Biotechnology · Cancer drugs · Commercial biotech · Urology · Thesis updated November 8, 2026

Zusduri sales surge as UroGen nears Q4 profitability

01 Running thesis

A launch that must carry the company

UroGen relies on the success of Zusduri. The drug replaces some repeat surgeries with local chemoablation, which places medicine directly in the bladder to destroy tumor tissue.

The launch continued to accelerate in the third quarter of 2026. Zusduri revenue reached $68 million, representing 35 percent sequential growth. Repeat prescribers now make up half of total writers, showing that doctors are adopting the treatment. Management expects this growth to push the company into profitability by the end of 2026.

The pipeline is also advancing. The FDA accepted the new drug application for UGN-103 and set a review target date of June 14, 2027. This drug will extend the franchise and reset patent protection to 2044.

The bear case highlights execution risk and valuation. The stock trades at a premium, scoring low on valuation metrics. The company carries a $250 million loan, and total success depends on scaling one primary product. Any slowdown in community practice adoption could derail the story.

Nov 2026▲Third-quarter 2026 results showed $68 million in Zusduri revenue. Management guided to reaching profitability in the fourth quarter, and the FDA set a June 2027 review date for UGN-103.
Aug 2026▲Second-quarter 2026 results showed 73 percent sequential growth for Zusduri. The company also settled the Teva patent litigation and secured a new patent extending protection into 2044.
May 2026▲First-quarter 2026 revenue rose to $51.0 million, led by $29.2 million from Zusduri. Patient conversion improved to 30 to 35 days, showing the permanent J-code is helping the launch.
Mar 2026▲The permanent J-code became effective on January 1, 2026, removing a key payment barrier for Zusduri. UroGen also refinanced $250 million of debt, pushing repayment to 2030.
Nov 2025▲Early Zusduri sales were still small, but the company received a permanent J-code expected to take effect in January 2026. UGN-103 also completed Phase 3 UTOPIA enrollment.
02 Business model

RTGel turns dwell time into a product

UroGen bases its platform on RTGel. This reverse-thermal hydrogel is liquid when given and then turns into a gel at body temperature. The goal is simple: keep cancer medicine in contact with urinary tract tissue for longer.

The company makes money from U.S. product sales of Jelmyto and Zusduri. Jelmyto treats low-grade upper tract urothelial cancer. Zusduri treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and is the main growth driver.

UroGen is expanding beyond urology. A new collaboration gives them access to a platform for treating solid tumors, including an option for a cisplatin gel targeting head and neck cancer.

This model can scale if urologists use the drugs often and payers keep paying without delays. It can break if community practices avoid the workflow or if single-source suppliers fail to deliver key compounds.

03 Product portfolio

Two commercial drugs and a growing pipeline

Growth engine

Zusduri

Zusduri is the main value driver. It generated $68 million in third-quarter 2026 revenue and has patent protection into 2044.

Cash cow

Jelmyto

Jelmyto is approved for adults with low-grade upper tract urothelial cancer. It produced $21 million of revenue in the third quarter of 2026.

Option

UGN-103

UGN-103 is a next-generation RTGel formulation. The FDA set a review action date of June 14, 2027, for its new drug application.

Option

UGN-104

UGN-104 is another RTGel-based formulation. It is currently in Phase 3 clinical trials.

Option

UGN-501

UGN-501 is an investigational virus designed to attack cancer cells. A Phase 1 trial dosed its first patient, with initial data expected in 2027.

Option

Cisplatin gel

Acquired through a collaboration, this Phase 2-ready therapy targets advanced head and neck cancer, moving UroGen beyond urology.

04 Business segments

Revenue depends heavily on one product

Zusduri product revenue76%growing fast
Jelmyto product revenue24%flat

UroGen reports one operating segment. In the third quarter of 2026, Zusduri made up 76 percent of the $89 million total product revenue, with the remainder from Jelmyto.

05 Risk factors

What could break the thesis

Zusduri growth slows down

High impact · Medium odds

The company depends entirely on the Zusduri launch. If community practice adoption slows or repeat utilization drops, revenue growth could stall.

We watchTrack quarterly Zusduri revenue, repeat prescription volume, and operating expenses.

Jelmyto faces clinical competition

Medium impact · Medium odds

Jelmyto is seeing increased competition for eligible patients from ongoing clinical trials in the low-grade space. This creates headwinds for new patient starts and can limit revenue.

We watchWatch quarterly Jelmyto sales and management commentary on patient starts.

UGN-103 faces regulatory delays

Medium impact · Medium odds

UGN-103 is important because it extends the franchise and resets patent protection. The FDA has set a June 2027 target date, but any delay or rejection would weaken the bridge to the next cycle.

We watchMonitor FDA updates ahead of the June 14, 2027 PDUFA date.

Supplier concentration bites

Medium impact · Low odds

UroGen relies on single-source suppliers for key compounds. A supply issue could limit product availability right when the launch needs clean execution.

We watchLook for new supply warnings, inventory comments, or manufacturing delay disclosures in filings.

Debt covenant restrictions

Medium impact · Low odds

The company must follow restrictive covenants under its $250 million loan facility. Failure to meet these terms could restrict future operations or harm financial health.

We watchMonitor quarterly debt compliance statements and cash burn rates.
06 Quick answers

In one breath

What does UroGen Pharma do?

UroGen develops and sells cancer treatments for the urinary tract. Its core technology, RTGel, helps medicine stay in contact with tissue for longer.

Why is Zusduri important for URGN stock?

Zusduri is the main growth driver. It produced $68 million of third-quarter 2026 revenue and is pushing the company toward profitability.

When will UGN-103 be approved?

The FDA accepted the application for UGN-103 and set a review target date of June 14, 2027.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. UroGen Q3 2026 earnings call transcript
  2. UroGen Q2 2026 Form 10-Q
  3. UroGen Q1 2026 earnings call transcript
  4. UroGen 2025 Form 10-K
08 Explore the industry

Comparable Biotechnology companies

Companies near UroGen Pharma Ltd. in Finn's Biotechnology industry ranking.

Get started with Finn today